-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice of petition.
SUMMARY:
The Food and Drug Administration (FDA) is announcing that E. & J. Gallo Winery has filed a petition proposing that the color additive regulations be amended to provide for the expanded safe use of mica-based pearlescent pigments as color additives in certain distilled spirits.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Raphael A. Davy, Center for Food Safety and Applied Nutrition (HFS-265), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3835, 240-402-1272.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
Under the Federal Food, Drug, and Cosmetic Act (section 721(d)(1) (21 U.S.C. 379e(d)(1))), notice is given that a color additive petition (CAP 2C0294) has been filed by E. & J. Gallo Winery, c/o Keller and Heckman LLP, One Embarcadero Center, Suite 2110, San Francisco, CA 94111. The petition proposes to amend the color additive regulations in 21 CFR 73.350 to provide for the safe use of mica-based pearlescent pigments prepared from titanium dioxide and mica as color additives in distilled spirits containing not less than 18% and not more than 23% alcohol by volume but not including distilled spirits mixtures containing more that 5% wine on a proof gallon basis.
The Agency has determined under 21 CFR 25.32(k) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
Start SignatureDated: March 13, 2012.
Francis Lin,
Acting Director, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition.
[FR Doc. 2012-6854 Filed 3-21-12; 8:45 am]
BILLING CODE 4160-01-P
Document Information
- Published:
- 03/22/2012
- Department:
- Food and Drug Administration
- Entry Type:
- Proposed Rule
- Action:
- Notice of petition.
- Document Number:
- 2012-6854
- Pages:
- 16784-16784 (1 pages)
- Docket Numbers:
- Docket No. FDA-2012-C-0224
- PDF File:
- 2012-6854.pdf
- CFR: (1)
- 21 CFR 73